Keywords: Bristol-Myers Squibb, Financial results, Fourth-quarter and full-year 2012
Bristol-Myers beats expectations, as new products kick in
Article | 25 January 2013
US drug major Bristol-Myers Squibb (NYSE: BMY) pleased investors, seeing its shares close up 2.6% at $35.81 yesterday, with its fourth-quarter and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
